NCT05142514View on ClinicalTrials.gov

Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)

PHASE2CompletedINTERVENTIONAL
Enrollment

629

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

December 27, 2021

Study Completion Date

May 6, 2022

Conditions
COVID-19SARS-CoV-2 Acute Respiratory Disease
Interventions
BIOLOGICAL

COVID-19 Vaccine HIPRA

Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart

BIOLOGICAL

Cominarty (Pfizer-BioNtech)

Subjects will receive 2 injections of Cominarty administered 21 days apart

Trial Locations (1)

Unknown

National Institute of Hygiene and Epidemiology, Hanoi

Sponsors

Collaborators (1)

Laboratorios Hipra, S.A.
All Listed Sponsors
collaborator

Laboratorios Hipra, S.A.

INDUSTRY

collaborator

National Institute of Hygiene and Epidemiology, Vietnam

OTHER

lead

Hipra Scientific, S.L.U

INDUSTRY

NCT05142514 - Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) | Biotech Hunter | Biotech Hunter